has been variously described as between 3 and 24 per second. 1 The occurrence of such rhythmic movements in human disease was first described by Parkinson2 in 1817, and since then it has repeatedly been shown that the pathologic changes associated with paralysis agitans are multiple and usually include the zona compacta of the substantia nigra, the globus pallidus, and the ansa lenticularis. Other regions sometimes involved include the neocortex, caudate nucleus, putamen, nucleus amygdalae, zona incerta, Forel fields H-1 and H-2, thalamus, hypothalamus, zona reticularis of the substantia nigra (Soemmerring's ganglion), corpus subthalamicum, mamillary bodies, and other structures of the midbrain, as well as the pons and medulla.3 Attempts to influence these rhythmic movements therapeutically have been limited largely to the use of various drugs, the majority of which are anticholinergic in action, with the exception of amyl nitrite, recently introduced by Garai.4 The results of surgical therapy are not entirely satisfactory,5 and it is evident that a